Absorption, Metabolism and Excretion of 14C-olorofim in Man
Status:
Completed
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
Single-centre, open-label, non-randomised, single dose study in 2 cohorts of healthy
subjects. It is planned to enrol 6 healthy male subjects in Cohort A (standard mass balance
and metabolite profiling cohort) and up to 6 subjects in Cohort B (biliary evaluation
cohort); each subject will receive a single oral administration of 120 mg [14C]-olorofim oral
solution containing approximately 3.7 MBq (100 µCi).